Levetiracetam Misses Primary Endpoint in Early Alzheimer Trial

Author profile image Aggregator
0 comments
A phase 2a crossover trial testing low-dose and high-dose levetiracetam in early Alzheimer disease did not significantly improve global cognition versus placebo.

Source: NeurologyLive Published 18 Nov 2026 Imported 18 Nov 2026 Relevancy: Not reviewed

Read the article